managing-ectopic-pregnancy

name	managing-ectopic-pregnancy
description	Guides ectopic pregnancy evaluation with beta-hCG trending and management algorithms. Use when evaluating ectopic pregnancy, trending beta-hCG, or managing ectopic treatment decisions.
tags	["management","obstetrics-and-gynecology","treatment","valuation"]
metadata	{"author":"casemark","practice_areas":["Obstetrics","Gynecology","Maternal-Fetal Medicine"],"document_types":["Management Report"],"skill_modes":["Management","Coordination"]}

Managing Ectopic Pregnancy

Guides ectopic pregnancy evaluation with serial β-hCG trending, discriminatory zone application, and evidence-based management algorithms per ACOG Practice Bulletin No. 193.

Why This Skill Exists

Ectopic pregnancy occurs in approximately 1–2% of all pregnancies and remains a leading cause of first-trimester maternal mortality. Ruptured ectopic pregnancy is a surgical emergency with potential for catastrophic hemorrhage. The critical clinical challenge is distinguishing ectopic from early intrauterine pregnancy (IUP) or pregnancy of unknown location (PUL) using serial β-hCG values and transvaginal ultrasound. The discriminatory zone — the β-hCG level above which an IUP should be visible on TVUS — is central to the diagnostic algorithm.

ACOG Practice Bulletin No. 193 (Tubal Ectopic Pregnancy) establishes the diagnostic criteria, methotrexate eligibility, and surgical indications. Errors in β-hCG interpretation, premature surgical intervention on a desired IUP, or delayed diagnosis of a ruptured ectopic have devastating clinical and medicolegal consequences.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. Symptoms — abdominal/pelvic pain (unilateral vs. bilateral), vaginal bleeding, shoulder pain, dizziness, syncope? (Default: from chief complaint)
2. LMP and estimated gestational age — how many weeks from LMP? (Default: from history)
3. Initial β-hCG level — quantitative serum value and date/time drawn? (Default: from lab results)
4. Ultrasound findings — IUP confirmed, adnexal mass, free fluid, empty uterus? (Default: from TVUS report)
5. Hemodynamic stability — vital signs, orthostatic symptoms, tachycardia, hypotension? (Default: current vitals)
6. Risk factors — prior ectopic, prior tubal surgery, PID history, IUD in situ, IVF pregnancy, smoking? (Default: from history)
7. Desire for future fertility — critical for management decision (medical vs. surgical)? (Default: patient preference)
8. Blood type and Rh status — RhoGAM needed if Rh-negative? (Default: from prenatal or current labs)

Documents to Request

• Serial β-hCG values with dates and times
• Transvaginal ultrasound reports (current and prior)
• CBC, type and screen, coagulation studies
• CMP (renal and liver function — required for methotrexate eligibility)
• Prior operative reports (tubal surgery, prior ectopic management)
• Pathology reports (if prior ectopic was treated surgically)

---

Step 1: Apply the Diagnostic Algorithm

β-hCG and the Discriminatory Zone

The discriminatory zone is the β-hCG level above which a viable IUP should be visible on TVUS:

• Discriminatory level: 3,500 IU/L (institutional range: 1,500–3,500 IU/L)
• Above discriminatory zone + no IUP on TVUS = abnormal pregnancy (ectopic or failed IUP)
• Below discriminatory zone + no IUP = pregnancy of unknown location (PUL) → serial β-hCG trending required

Expected β-hCG Rise in Normal IUP

• Early viable IUP: β-hCG rises by at least 53% in 48 hours (minimum normal rise, per ACOG)
• The traditional "doubling time of 48 hours" applies to early pregnancies (β-hCG < 10,000)
• Slower rise may still be normal; < 53% rise in 48 hours is abnormal and suggests ectopic or nonviable IUP

β-hCG Decline Patterns

• After completed miscarriage: β-hCG should decline by ≥ 21–35% in 48 hours
• Slower than expected decline suggests retained products or ectopic
• Plateau (neither rising nor falling adequately) is concerning for ectopic

Decision Matrix

Scenario	β-hCG Trend	Ultrasound	Action
Normal IUP	Rising ≥ 53%/48 hrs	IUP confirmed	Routine prenatal care
Ectopic confirmed	Any level	Adnexal mass + no IUP; or extrauterine gestational sac with yolk sac/embryo	Manage ectopic (medical or surgical)
PUL — likely viable IUP	Rising ≥ 53%/48 hrs	Empty uterus, below discriminatory zone	Repeat β-hCG in 48–72 hrs + TVUS when above discriminatory zone
PUL — likely nonviable	Rising < 53%/48 hrs or plateauing	Empty uterus	Ectopic vs. failing IUP; consider D&C with path or serial monitoring
PUL — declining	Falling > 50% in 48 hrs	Empty uterus	Likely completed miscarriage; follow to β-hCG < 5
Ruptured ectopic	Any level	Free fluid, hemodynamic instability	Emergent surgery — do not delay

---

Step 2: Methotrexate (Medical Management)

Eligibility Criteria for Methotrexate

Criteria	Requirement
Hemodynamic stability	Required — unstable patients → surgery
Ectopic mass size	≤ 3.5 cm (per ACOG; some extend to 4 cm)
No fetal cardiac activity on US	Required (cardiac activity = relative contraindication, higher failure rate)
β-hCG level	< 5,000 IU/L ideal; success rate drops above 5,000
Patient ability to follow up	Must be able to return for serial β-hCG monitoring
Renal function	Normal creatinine
Hepatic function	Normal transaminases
WBC count	> 1,500/μL
Platelet count	> 100,000/μL
No immunodeficiency	—
No breastfeeding	Methotrexate is contraindicated in breastfeeding

Methotrexate Protocols

Protocol	Dosing	Monitoring
Single-dose	MTX 50 mg/m² IM (day 1)	β-hCG days 4 and 7; if < 15% decline between days 4–7, give second dose
Two-dose	MTX 50 mg/m² IM days 1 and 4	β-hCG days 4 and 7; if < 15% decline between days 4–7, give doses on days 7 and 11
Multi-dose	MTX 1 mg/kg IM on days 1, 3, 5, 7 alternating with leucovorin 0.1 mg/kg on days 2, 4, 6, 8	β-hCG before each MTX dose; stop when 15% decline achieved

Post-methotrexate monitoring:

• Weekly β-hCG until < 5 IU/L
• Avoid NSAIDs, folate supplements, alcohol, and intercourse until resolved
• Warn about transient β-hCG rise between days 1–4 (expected, not treatment failure)
• Watch for treatment failure signs: increasing pain, hemodynamic change, rising β-hCG after day 7

---

Step 3: Surgical Management

Indications for Surgery

• Hemodynamic instability (ruptured ectopic)
• Contraindication to methotrexate
• Failed methotrexate (rising β-hCG after day 7 of second dose)
• Patient preference
• Fetal cardiac activity on ultrasound
• β-hCG > 5,000 IU/L (higher failure rate with medical management)

Surgical Options

Procedure	Description	Fertility Considerations
Salpingostomy	Linear incision over ectopic, removal of products, tube preserved	Preferred if contralateral tube is damaged or absent
Salpingectomy	Complete removal of affected tube	Preferred if contralateral tube is healthy; lower recurrence risk

Post-surgical:

• Follow β-hCG weekly to < 5 IU/L (persistent ectopic tissue requires retreatment in 5–20% of salpingostomy cases)
• RhoGAM if Rh-negative (50 mcg if < 12 weeks, 300 mcg if ≥ 12 weeks)
• Pathology confirmation of ectopic tissue

---

Step 4: Special Situations

Heterotopic Pregnancy

• Coexisting IUP + ectopic; incidence is 1:30,000 naturally but up to 1:100 with ART
• Methotrexate is contraindicated (would harm the IUP)
• Treatment: surgical removal of ectopic with preservation of IUP

Interstitial (Cornual) Ectopic

• Located in intramural portion of the tube
• Higher rupture risk with more severe hemorrhage
• May present later (up to 12–16 weeks) due to myometrial distensibility
• Surgical: cornual resection or cornuostomy; consider uterine artery embolization

Cesarean Scar Ectopic

• Implantation within the cesarean scar niche
• Increasing incidence with rising cesarean rates
• Management: methotrexate, uterine artery embolization, hysteroscopic resection, or laparotomy

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the β-hCG trend documented with at least two values, dates, and calculated % change?
2. Is the discriminatory zone applied correctly — and does the action match the scenario?
3. Are methotrexate eligibility criteria checked before recommending medical management?
4. Is Rh status addressed with RhoGAM administered or planned if Rh-negative?
5. Is the follow-up plan explicit — serial β-hCG schedule, return precautions, and failure criteria?

---

Quality Audit

• Quantitative β-hCG documented with date, time, and serial values
• β-hCG trend calculated (% rise or decline in 48 hours)
• Discriminatory zone defined (institutional threshold stated)
• TVUS findings documented (IUP present/absent, adnexal mass, free fluid)
• Hemodynamic status documented
• Risk factors for ectopic documented
• Methotrexate eligibility criteria systematically checked (all elements)
• Methotrexate protocol specified (single-dose, two-dose, or multi-dose) with dosing
• Post-methotrexate monitoring schedule documented
• Surgical indication documented (if operative management chosen)
• Procedure type documented (salpingostomy vs. salpingectomy) with rationale
• Rh status documented and RhoGAM administered/planned
• Pathology confirmation of ectopic tissue documented (surgical cases)
• Patient counseled on ectopic precautions (pain, bleeding, return to ED)
• β-hCG follow-up schedule documented until < 5 IU/L

---

Guidelines

1. Never diagnose ectopic based on a single β-hCG — serial values and ultrasound findings are required for diagnosis (unless ultrasound shows definitive extrauterine pregnancy with cardiac activity).
2. The discriminatory zone is a guideline, not an absolute — multiple gestations and early IUPs may not be visible at the traditional threshold; use caution before intervening on a desired pregnancy.
3. A rising β-hCG does not exclude ectopic — ectopic pregnancies can show normal-appearing rises in up to 21% of cases.
4. Methotrexate is not risk-free — it requires reliable patient follow-up; do not administer if the patient cannot return for serial monitoring.
5. Ruptured ectopic is a surgical emergency — hemodynamic instability with a positive pregnancy test and free fluid mandates immediate operative intervention without waiting for β-hCG trends.
6. Salpingectomy is preferred when the contralateral tube is healthy — it eliminates the risk of persistent ectopic and recurrence in the same tube.
7. Follow β-hCG to zero after ANY ectopic management — persistent trophoblastic tissue occurs in 5–20% of salpingostomy cases and requires surveillance.
8. Always give RhoGAM to Rh-negative patients — ectopic pregnancy is a sensitizing event.